Mundipharma appoints Paul Medeiros as head of corporate and business development

pharmafile | March 6, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Cambridge, Medeiros, Mundipharma 

Mundipharma International has appointed Paul Medeiros as its new head of corporate and business development at its Cambridge, UK site. 

In this position, Medeiros will help corporate growth within Mundipharma’s European network of independent associated companies.

He brings over 19 years of experience in biopharmaceutical business development and a significant track record of success in technology acquisitions. 

He most recently served as senior vice president and chief business officer at AVI BioPharma, an RNA-based therapeutics firm for rare diseases. 

Advertisement

In that role, he was responsible for all business development and licensing activity, establishment of academic and commercial research collaborations, product portfolio planning and corporate strategy development. 

Previously, Medeiros served as VP of global licensing and strategic alliances for Schering-Plough, where he led worldwide product licensing and strategic partnering initiatives in specialist product categories.

Medeiros began his pharma career at Merck, where he held positions in field sales, new product planning and worldwide marketing.

 

Related Content

Addenbrooke’s hospital offers first self-service digital eye test

Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …

european_commission_web

Europe extends Invokana indication to cover diabetic kidney disease in type 2 diabetes patients

European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making …

cq5dam

AstraZeneca spends more than twice as much as expected on new HQ

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the …

The Gateway to Local Adoption Series

Latest content